Data sourcesSEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago
Public companyCandel Therapeutics, Inc.
CADLCIK 0001841387
Price$8.75
1 year+71.9%
Disclosed transactions15
Buys / sells0 / 5
Max Insider Score26
Connections with evidence11
CADL · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | OMOstrovsky MariaGeneral Counsel | CADLCandel Therapeutics, Inc. Grant or award | A | — 315.0K sh | Nov 3, 2026 | Nov 5, 2026 |
| 26 | TPTak Paul PeterDirector, Chief Executive Officer | CADLCandel Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $2.54M 220.9K sh | Sep 10, 2026 | Sep 11, 2026 traded Sep 10, 2026 | +1d | SEC Form 4 | |
| 10 | TPTak Paul PeterDirector, Chief Executive Officer | CADLCandel Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $194K 125.0K sh | Sep 10, 2026 | Sep 11, 2026 traded Sep 10, 2026 | +1d | SEC Form 4 | |
| 3 | TPTak Paul PeterDirector, Chief Executive Officer | CADLCandel Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 125.0K sh | Sep 10, 2026 | Sep 11, 2026 traded Sep 10, 2026 | +1d | SEC Form 4 | |
| 15 | TPTak Paul PeterDirector, Chief Executive Officer | CADLCandel Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $621K 59.4K sh | Sep 11, 2026 | Sep 11, 2026 traded Sep 11, 2026 | +0d | SEC Form 4 | |
| 8 | TSTyagarajan SeshuChief Technology Officer | CADLCandel Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $84K 7,000 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC Form 4 | |
| 17 | TSTyagarajan SeshuChief Technology Officer | CADLCandel Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $70K 7,000 sh | Jun 29, 2026 | Jul 1, 2026 traded Jun 29, 2026 | +2d | SEC Form 4 | |
| 21 | BFBarone FrancescaChief Scientific Officer | CADLCandel Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $236K 23.4K sh | Jun 29, 2026 | Jul 1, 2026 traded Jun 29, 2026 | +2d | SEC Form 4 | |
| 9 | LNLoggia NicolettaDirector | CADLCandel Therapeutics, Inc. Grant or award | A | $3,291 381 sh | Jun 30, 2026 | Jul 1, 2026 traded Jun 30, 2026 | +1d | SEC Form 4 | |
| 9 | LNLoggia NicolettaDirector | CADLCandel Therapeutics, Inc. Grant or award | A | — 32.0K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 9 | MCMartell ChristopherDirector | CADLCandel Therapeutics, Inc. Grant or award | A | — 32.0K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 9 | RMRadhakrishnan MahaDirector | CADLCandel Therapeutics, Inc. Grant or award | A | — 32.0K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 9 | | CADLCandel Therapeutics, Inc. Grant or award | A | — 32.0K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 9 | | CADLCandel Therapeutics, Inc. Grant or award | A | — 32.0K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
| 9 | | CADLCandel Therapeutics, Inc. Grant or award | A | — 32.0K sh | Jun 23, 2026 | Jun 24, 2026 traded Jun 23, 2026 | +1d | SEC Form 4 | |
Chief Technology Officer · Jul 1, 2026